BNTCHealthcare · BiotechnologyBNTC Stock Forecast: Benitec Biopharma, Inc. Price Predictions for 2026-2027
The 7 Wall Street analysts covering Benitec Biopharma, Inc. hold a median 12-month price target of $25 — +92.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 22 Aug 2026 — in the lower half.
BNTC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Benitec Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (76): The business earns solid, repeatable profits on what it owns.
Growth (30): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
BNTC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BNTC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +92.8% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 28 July 2026 | Wedbush | Initiates | Outperform | $16 |
| 12 May 2026 | Evercore ISI Group | Initiates | Outperform | $25 |
| 12 May 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 9 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 4 Nov 2025 | Citizens | Maintains | Market Outperform | — |
| 4 Nov 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 24 Sept 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 16 Sept 2025 | Oppenheimer | Maintains | Outperform | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 May 2025 | JMP Securities | Reiterates | Market Outperform | — |
| 10 Apr 2025 | JMP Securities | Maintains | Market Outperform | — |
| 24 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 18 Mar 2025 | Citizens Capital Markets | Reiterates | Market Outperform | — |
| 21 Feb 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Dec 2024 | Baird | Initiates | Outperform | — |
| 3 Dec 2024 | Guggenheim | Reiterates | Buy | — |
| 16 Oct 2024 | Oppenheimer | Initiates | Outperform | $35 |
| 14 Oct 2024 | JMP Securities | Maintains | Market Outperform | $16 → $18 |
| 30 Sept 2024 | JMP Securities | Reiterates | Market Outperform | $16 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BNTC appears on the weeks it earns a place.
BNTC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Benitec Biopharma, Inc. returned −2.2% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BNTC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Benitec Biopharma, Inc. (BNTC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −12.9×
- Price / sales
- —
- Price / book
- 2.5×
- EV / EBITDA
- −6.0×
Cheaper than 94% of US stocks
Cheaper than 40% of US stocks
Cheaper than 79% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- −29.6%
- Return on assets
- −19.9%
- Dividend yield
- —
Higher than 27% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Benitec Biopharma, Inc. (BNTC) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Benitec Biopharma, Inc. has a market value of $463.1M and an enterprise value of $279.2M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$48.9M.
Free cash flow in the twelve months to 31 Mar 2026: −$19.8M.
Trailing P/E: −12.9×; forward P/E: −1.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Benitec Biopharma, Inc. employs 19 people.
Data provided by Twelve Data
BNTC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Benitec Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about BNTC stock
What is the BNTC stock price forecast for 2026-2027?
The 7 Wall Street analysts covering Benitec Biopharma, Inc. have a median 12-month price target of $25, with estimates ranging from $16 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BNTC stock a buy right now?
Of the 7 analysts covering Benitec Biopharma, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Benitec Biopharma, Inc. 42 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BNTC?
As at 22 Aug 2026, Benitec Biopharma, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (76 of 100).
Will BNTC stock go up?
No one can know that. What the data says: the median 12-month target from 7 analysts implies +92.8% from the last close, and Ticker Nerd's factor model ranks Benitec Biopharma, Inc. 42 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BNTC stock forecast for 2030?
No analyst covering Benitec Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BNTC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $32 over the next 12 months.
How has BNTC stock performed over the past year?
Benitec Biopharma, Inc. returned -2.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Benitec Biopharma, Inc. do?
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines for chronic and life-threatening conditions.
About Benitec Biopharma, Inc.
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on developing novel genetic medicines for chronic and life-threatening conditions. It employs its proprietary Silence and Replace platform, which combines DNA-directed RNA interference with gene therapy to enable sustained silencing of disease-causing genes and delivery of replacement genes via a single administration. The lead product candidate, BB-301, is an AAV-based gene therapy targeting dysphagia associated with oculopharyngeal muscular dystrophy, a genetic disorder affecting swallowing function. This platform addresses unmet needs in gene-associated diseases lacking effective treatments. Benitec Biopharma Inc. operates within the biotechnology sector of healthcare, advancing therapeutics through clinical trials and regulatory interactions, including Fast Track and Orphan Drug designations. Headquartered in Hayward, California, the company contributes to innovative solutions in genetic medicine by leveraging RNAi and gene therapy technologies.
CEO Dr. Jerel A. Banks M.D., Ph.D. · 19 employees · United States · https://benitec.com